Stalicla

New results to be Presented at The BRAIN Foundation Synchrony 2020 Conference

STALICLA will present new data from the biological characterization of a novel DEPI-identified endophenotype within Autism Spectrum Disorder (ASD): ASD Phenotype 1 (ASD-Phen1) at The BRAIN Foundation Synchrony 2020 conference Dec. 12th 2020. About the Presentation at Synchrony SymposiumMs Lynn Durham’s presentation entitled “Creating an Integrated Framework to Enable Precision Medicine Drug Development and Clinical Trials in ASD” will …

New results to be Presented at The BRAIN Foundation Synchrony 2020 Conference Read More »

Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A

GENEVA–(BUSINESS WIRE)–STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) – including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay – today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M). The round …

Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A Read More »

STALICLA appoints Stéphane Baudouin as Chief of Science

Neurobiologist with ten years’ Autism Spectrum Disorder experience takes on the lead research strategy role at the Swiss biotech. Geneva & Barcelona – STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant …

STALICLA appoints Stéphane Baudouin as Chief of Science Read More »

STALICLA’s CEO & Founder, speaker at the Royal Netherlands Academy of Sciences Colloquium – October 2-3 2019

STALICLA’S CEO & Founder, Lynn Durham invited as a speaker to the Royal Netherlands Academy of Arts and Sciences Colloquium on Neurodevelopmental Disorders  – October 2-3 2019 Lynn Durham has been invited as a speaker together with a group of world leading experts at the prestigious Royal Netherlands Academy to participate in its Colloquium entitled “A …

STALICLA’s CEO & Founder, speaker at the Royal Netherlands Academy of Sciences Colloquium – October 2-3 2019 Read More »

Lynn Durham to present at the SACHS Associates Biotech in Europe Forum, Basel – September 25-26

STALICLA to present at the SACHS Associates Biotech in Europe Forum, Basel – September 25-26 CEO, Lynn Durham, will represent STALICLA at the 19thAnnual Biotech in Europe Forum. Lynn will be speaking on day 1, with a company presentation (14:00 – 14:15 CET, 25thSeptember) and as a Panellist on the Neurosciences Panel 1 (16:05 – …

Lynn Durham to present at the SACHS Associates Biotech in Europe Forum, Basel – September 25-26 Read More »